Alpha-Fetoprotein (AFP) is the Primary Tumor Marker for Immature Teratoma
AFP is the most clinically relevant tumor marker for immature teratoma, with elevated levels found in 57-62% of cases, making it the primary marker for diagnosis, monitoring treatment response, and detecting recurrence 1, 2.
Tumor Marker Profile
Alpha-Fetoprotein (AFP)
- Elevated in 57.1-61.9% of immature teratomas 1, 2
- More commonly elevated when yolk sac tumor elements are present (83% positivity) 3
- Essential for monitoring during follow-up after surgical resection 4, 3
- Elevated AFP in ovarian immature teratoma does not necessarily mandate chemotherapy if completely resected 3
Other Markers
- CA-125: Elevated in 40.9% of immature teratomas, useful for screening malignant germ cell tumors but less specific 2, 5
- Beta-hCG: Elevated in only 16.7% of immature teratomas 1
- CA19-9: Shows high positivity in teratomatous tumors but not specific for immature forms 2
- LDH: Not particularly useful for immature teratomas specifically 2
Clinical Application Algorithm
At Diagnosis
- Measure AFP preoperatively - elevated in majority of cases
- Check CA-125 as secondary marker
- Beta-hCG has limited utility but may be included in germ cell tumor panel
Post-Surgical Monitoring
- Serial AFP measurements are critical for detecting recurrence 4, 3
- Recurrences typically occur 4-7 months post-diagnosis 4
- Elevated or rising AFP during surveillance indicates recurrence requiring platinum-based chemotherapy
Important Caveats
Pure immature teratomas without yolk sac elements may have normal AFP levels - approximately 34-40% of cases will not show elevation 3, 2. This does not exclude the diagnosis.
The presence of elevated AFP, particularly when combined with tumor size >10 cm and ascites, strongly suggests immature rather than mature teratoma 5.
Unlike seminomas (which never produce AFP per guideline standards 6, 7), immature teratomas can have variable AFP expression depending on the presence of yolk sac tumor components.